CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Summary

In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10\^6/kg-1×10\^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma.

Timeline

Start

2017-06-08

Primary completion

2019-05-22

Completion

2021-06-22

Publications

• Liu W, Xie T, Zhang Z, Huang W, Liu H, Sui W, Deng S, Lyu R, Wang Y, Wang Q, Xiong W, Xu Y, Lyu L, Ma Y, Qiu L, Wang J, Zou D. Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma. Chin Med J (Engl). 2026 May 5;139(9):1367-1374. doi: 10.1097/CM9.0000000000003716. Epub 2025 Sep 17.

Drugs

Indications